Sixty years of asking bone to rebuild
Bone regeneration was not discovered once — it was earned, laboratory by laboratory, signal by signal. These are the names and the years, drawn from the public record. Where Panacea's own work enters the timeline, it is marked as in-house and unverified.
1965Marshall Urist — bone can make bone
Orthopaedic surgeon Marshall R. Urist at UCLA publishes in Science the observation that demineralised segments of bone induce new bone formation when implanted in muscle pouches in rabbits. Whatever lived inside the bone matrix could recruit and instruct bone-building cells — the founding fact of bone-regeneration science.
Urist M.R., Science 150, 893 (1965) · background
1971The signal gets a name
Urist proposes the term "bone morphogenetic protein" in the Journal of Dental Research — naming the matrix-bound signal responsible for the induction he had described. The hunt to isolate it begins.
1980sReddi purifies; Wozney clones
A. Hari Reddi's laboratory drives the biochemical purification of the osteogenic proteins from bone matrix, work that enables John Wozney and colleagues at Genetics Institute to clone the BMPs. Their 1988 Science paper — "Novel regulators of bone formation: molecular clones and activities" — turns a mysterious matrix activity into a family of named, manufacturable molecules of the TGF-β superfamily.
Wozney J.M. et al., Science 242, 1528 (1988) · background
2001rhBMP-7 reaches the clinic
The FDA approves recombinant human BMP-7 (OP-1; Stryker Biotech) under a humanitarian device exemption as an alternative to autograft in long-bone nonunions — the first regulatory approval of an externally supplied osteogenic signal to drive human bone formation.
2002rhBMP-2 and the anabolic peptide
Recombinant BMP-2 (Infuse; Medtronic) is approved for anterior lumbar interbody fusions, later extended to other uses — alongside documented debate about dosing, overgrown bone and off-label use. The same year, the FDA approves teriparatide (Forteo), the recombinant PTH 1-34 fragment: an anabolic agent that stimulates osteoblasts and new bone formation in some forms of osteoporosis. A peptide — 34 amino acids — as a bone-building medicine.
2010s–2026The osteogenic-peptide wave
Attention shifts from whole proteins to their active sentences: short peptide motifs derived from BMP-2, PTH-related protein and other osteogenic signals, carried on hydrogels, scaffolds and 3D-printed matrices. The literature is now a steady stream of preclinical studies — mechanism-guided therapeutic peptides, peptide-engineered vesicles, BMP-2 composite scaffolds — almost all none a finished therapy, all pointed at tunable, manufacturable bone-formation signals.
2026Panacea Bio Chem — the OsteoFast record
Panacea Bio Chem's contribution at this date is a research position, not a product: the OsteoFast programme applies the house's peptide design, low-temperature lyophilisation and S3Pulse™ biointegrity monitoring to osteogenic peptide candidates — the fragile end of the field, where keeping a short chain intact from synthesiser to bench is half the battle. Candidate sequences and process parameters remain Panacea intellectual property — the house's programme, pursued with the same rigor as everything else Panacea ships.
Panacea in-house research record · forward-looking research position